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Summary
Background: Rosacea is a common chronic inflammatory cutaneous disorder affec-
ting nearly 5.5 % of the adult population. Our aim was to evaluate the prevalence and 
epidemiology of rosacea and perioral dermatitis (POD) in an ambulatory care setting.
Methods: We retrospectively analyzed medical data of patients with a confirmed 
diagnosis of rosacea or perioral dermatitis (POD) presenting at our university hospital 
outpatient clinic during a 3-year period.
Results: Out of 1032 patients, 81.5 % were diagnosed with rosacea and 18.5 % with 
POD. Overall prevalence was 1.4 % for rosacea and 0.3 % for POD. 69.3 % of the analy-
zed patients were female. Overall mean age was 49.3 ± 7.7 (1–92) years; the women’s 
average age was less than the men’s. Patients with POD were younger and predomi-
nantly female, whereas patients with phymatous rosacea were older and predomi-
nantly male. The most common phenotypes were papulopustular rosacea (68.4 %), 
erythematotelangiectatic rosacea (22.5 %), and phymatous rosacea (8.0 %). Special 
forms of rosacea were diagnosed in 15.8 % of the patients; the most frequent were 
ocular rosacea (6.9 %) and steroid-induced rosacea (5.4 %).
Conclusions: The large patient cohort analyzed in our study provides a good estima-
te of the frequency of the rosacea subtypes, special forms and of perioral dermatitis in 
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Rosacea is a common cutaneous disorder that primarily 
affects the central face, and is most frequently observed in 
individuals with lightly pigmented skin [1, 2]. Current epi-
demiological data related to rosacea is scarce and partially 
controversial. The prevalence of rosacea is difficult to assess 
due to inconsistent definitions, variable clinical manifesta-
tions and the wide range of skin diseases that exhibit similar 
clinical features, as well as cultural and social perceptions of 
the disease [3, 4]. A multicenter, cross-sectional study from 
2016 reported a prevalence of 5 % and 12 % for Russia and 
Germany, respectively [5]. A recent meta-analysis estimates 
the overall global prevalence of rosacea in the adult popula-
tion at 5.46 % [6].
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However, a limiting factor is the lack of a commonly ac-
cepted international classification that describes the different 
forms of rosacea accurately without leaving a broad scope for 
interpretation. Because rosacea patients often present with a 
wide range of skin symptoms and various clinical presenta-
tions, precise clinical classification is often challenging [7].
Most studies concerning the different forms of rosacea 
have used a subtype-oriented classification. Based on cur-
rent scientific knowledge and morphologic characteristics, 
a global assessment has distinguished four main subtypes 
(S. 1–4): erythematotelangiectatic (ETR, S. I), papulopustu-
lar (PPR, S. II), phymatous (S. III) and ocular rosacea (S. 
IV), which is an ocular manifestation of rosacea that involves 
the eyelids and the front of the eye, and includes blepharitis, 
conjunctival hyperemia, and rosacea-associated keratitis [8].
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However, the latest attempts towards an approach ba-
sed on phenotype rather than subtype to the diagnosis and 
classification of rosacea are linked to our increased under-
standing of disease pathophysiology, and have received in-
ternational acceptance [7, 9, 10]. Rosacea may begin with a 
transient, primarily centrofacial erythema. It can also pre-
sent as an ETR (severity grade I), as a PPR (severity grade II), 
or as a glandular/hyperplastic form (phymatous rosacea, se-
verity grade III). Since the diagnosis is generally clinically 
determined, it is crucial that physicians consider the diffe-
rential diagnoses (DDs) for each of the severity forms, such 
as carcinoid syndrome, menopause-induced flushing, UV-in-
duced cutaneous vascular damage (DD: transient erythe-
ma), polycythemia vera, lupus erythematosus (DD: ETR), 
papulopustular acne, perioral dermatitis (DD: PPR), lupus 
pernio and eosinophilic granuloma (DD: glandular/hyper-
plastic rosacea). These phenotypes can occur isolated or in 
combination [9, 11, 12]. Furthermore, rosacea can present 
with abnormal or unusual symptoms and progression. These 
special forms include ocular rosacea, steroid-induced rosa-
cea, rosacea fulminans, granulomatous rosacea, Morbihan 
disease, gram-negative rosacea, rosacea conglobata, and pe-
diatric rosacea [11, 12]. Data concerning the distribution of 
the special forms is rare and the prevalence of each of these 
forms is still unclear.
Additionally, patients with perioral dermatitis (POD) 
can present with symptoms similar to those of rosacea and 
complicate differentiation from rosacea’s special forms.
Therefore, a thorough analysis of a large cohort of ro-
sacea patients presenting in the outpatient clinic of the De-
partment of Dermatology and Allergy of the Ludwig-Ma-
ximilian-University (LMU) might contribute to a better 
understanding of the epidemiology of rosacea in a clinical 
setting, especially concerning the phenotypes and special 
forms of the disease.
Material and methods
Ethics
This study was approved by the ethics committee of the me-
dical faculty of the LMU, Munich, Germany (Ref.-No. 080-
14) and complies with the principles of the Declaration of 
Helsinki. Patient information and identification were kept 
confidential at all times and the data analysis was performed 
anonymously.
Inclusion criteria
Patients’ data were collected from the digital files of the 
Dermatology Department of the LMU. Our inclusion crite-
ria comprised patients with a confirmed diagnosis by ICD-
10 code (L71.0 for perioral dermatitis [POD], L71.1 for 
rhinophyma, L71.8 for other forms of rosacea, and L71.9 for 
unspecified forms of rosacea). Patients were recruited bet-
ween Jan 1st, 2012 and Dec 31st, 2014. They were selected 
independently of age, gender, or origin.
Exclusion criteria
Since some of the patients had several consultations during 
the period from 2012–2014, only the first consultation of 
each patient was considered for further analysis in order to 
eliminate bias.
Statistics
Standard descriptive statistics such as the mean, standard de-
viation and standard error of the mean were calculated with 
statistics software (SPSS version 22, IBM, NY/USA).
Results
Patients
Of the 1032 included patients, 841 (81.5 %) had been diag-
nosed with rosacea (ICD-10 L71.1, L71.8 or L71.9) and 191 
(18.5 %) with perioral dermatitis (POD, ICD-10 L71.0). The 
prevalence of patients with rosacea was 1.4 % (nrosacea/ntotal = 
841/60,965) and 0.3 % (nPOD/ntotal = 191/60,965) for POD of 
all treated patients during that period of time.
Age and Gender
The mean age of all patients was 49.3 ± 17.7 (1–92) years. 
Children (< 18 years old) comprised only 0.8 % (n = 8) of the 
analyzed cohort. Patients who presented with rosacea were 
slightly older than average (51.6 ± 17 [1–92] years) while 
those diagnosed with perioral dermatitis were approximately 
eleven years younger than the overall average (38.7 ± 17.3 
[1–77] years). When compared by gender, female patients 
who received either of these diagnoses tended to present ear-
lier (48.5 ± 17.7 [1–92] years) than male patients (50.9 ± 17.8 
[1–86] years).
Patients presenting with phymatous rosacea and ocular 
rosacea were diagnosed at a notably higher mean age than 
the overall average, respectively at 60.3 ± 14.3 (26–84) and 
54.0 ± 17.7 (15–82) years old. However, the average age of 
the remaining special forms of rosacea was lower than the 
mean of the total study cohort (49.3 ± 17.7 [1–92] years) 
(Table 1).
Overall, 715 (69.3 %) of all patients were female, of 
which only five (0.7 %) were pregnant or breastfeeding. 
This percentage was slightly less in patients with rosacea 
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(64.6 %, n = 543/841), but was much higher in patients with 
POD (90.1 %, n = 172/191). In contrast, when the severest 
form of rosacea was investigated, patients diagnosed with 
phymatous rosacea were predominantly male (71.8 %, n = 
56/78) (Table 1).
Clinical Symptoms
Analysis of the patient data resulted in a clear diagnosis 
in 1032 cases, but a detailed documentation of symptoms 
was only provided in 942 cases. Based on the descriptions 
of the symptoms of these cases, the most frequent primary 
efflorescences detected in patients with rosacea or POD 
were papules, persistent erythemata, telangiectasias and 
pustules; these were respectively observed in 64.8 % (n = 
610/942), 56.2 %, 39.1 % and 30.5 % of patients, and 
occurred in various combinations (Figure 1). Furthermo-
re, 689 patients (73.1 %) also reported a variety of other 
symptoms with the most prominent being pruritus (19.6 %, 
n = 135/689), closely followed by erythematous plaques 
(18.7 %) and desquamation (16.0 %). Ocular involvement 
and rhinophyma were identified in only 10.0 % and 9.3 % 
of cases, respectively (Figure 2). The ocular manifestation 
of rosacea was mainly detected in the form of conjunctivi-
tis or blepharitis
Phenotypes
We were able to accurately evaluate the phenotypes of 975 pa-
tients (94.5 %) out of a total of 1032 that were included. We 
found that erythematotelangiectatic rosacea (ETR) (72.7 %, 
n = 709/975) and papulopustular rosacea (PPR) (72.4 %) did 
not differ significantly from each other when compared by 
the frequencies of their appearances (cumulated). However, 
if the phenotype were to be determined by the severest sym-
ptom, PPR (68.4 %) would clearly be the leading symptom, 
Table 1 Distribution of rosacea, POD, phenotypes (severity-oriented) and special forms related to sex and age. The table sums 
up the main results of the study and gives an overview of the general distribution of the phenotypes and special forms of rosa-
cea, divided into total number of patients, gender and mean age.






Total 1032 (100) 715 (69.3) 49.3 ± 17.7 (1–92)
Rosacea 841 (81.5) 543 (64.6) 51.6 ± 17.0 (1–92)
POD 191 (18.5) 172 (90.1) 38.7 ± 17.3 (1–77)
Severity of phenotypes
Rosacea diathesis (transient 
erythema)
11 (1.1) 7 (63.6) 46.3 ±15.3 (22–76)
ETR 219 (22.5) 160 (73.1) 52.4 ± 17.7 (15–86)
PPR 667 (68.4) 490 (73.5) 47.0 ± 17.5 (0–92)
Phymatous rosacea 78 (8.0) 22 (28.2) 60.3 ± 14.2 (26–84)
(975 documented phenotypes)
Special forms
Ocular rosacea 69 (6.9) 49 (71.0) 54.0 ± 17.7 (15–82)
Rosacea conglobata 2 (0.2) 1 (50.0) 40.5 ± 6.4 (36–45)
Rosacea fulminans 8 (0.8) 6 (75.0) 48.4 ± 17.1 (27–75)
Gram-negative rosacea 1 (0.1) 1 (100) 42 ± 0 (42)
Steroid-induced rosacea 54 (5.4) 42 (77.8) 42.4 ± 19.5 (1–81)
Granulomatous rosacea 14 (1.4) 7 (50.0) 43.9 ± 17.7 (21–86)
Morbihan disease 10 (1.0) 6 (60.0) 43.4 ± 11.4 (25–60)
Rosacea in children 8 (0.8) 4 (50.0) 5.4 ± 4.8 (1–13)
(166 documented special forms in 158 patients)
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Figure 1 Distribution of the main symptoms of rosacea. This shows the frequency of the main facial symptoms or the various 
combinations with which the patients presented in our dermatologic outpatient clinic.
Figure 2 Distribution of patient-reported symptoms (black horizontal bars) and all other symptoms (blue horizontal bars). It 
shows all other symptoms that were documented in the patients’ first consultations in our dermatology outpatient clinic.
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followed by ETR (22.5 %) and phymatous rosacea (8.0 %). 
Rosacea diathesis (transient erythema) was detected in only 
1.1 % of all patients (Figure 3).
The most frequently observed phenotype combination 
was that between PPR and ETR (45.3 %) (Figure 4).
Special forms
Out of 1032 patients, 1000 (96.9 %) were further analyzed 
regarding the special forms of rosacea. Of this patient cohort, 
158 (15.8 %) were diagnosed with special forms of rosacea. 
Figure 3 Distribution of the pheno-
types of rosacea based on a cumula-
ted-oriented and a severity-oriented 
determination of symptoms.
Figure 4 Individual and combined occurrence of different phenotypes in the clinical presentation of the patients.
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They occurred alone, in combination with the classic form 
and in a few cases two special forms occurred together in 
the same patient. Ocular rosacea, described in the medical 
notes as ocular involvement with symptoms such as blepha-
ritis, conjunctivitis, dry and/or burning eyes, showed the 
highest prevalence in this category with 6.9 %, followed by 
steroid-induced rosacea with 5.4 % of the evaluated patients. 
Other special forms such as granulomatous rosacea, pediatric 
rosacea and rosacea fulminans were diagnosed at a very low 
rate of less than 1.0 % each (Figure 5). Morbihan disease/
persistent edema was clinically diagnosed in 10 cases (1.0 %), 
of which only two were confirmed (by histological exclusion 
of several differential diagnoses) as Morbihan disease.
Therapy
Overall, 899 out of 1032 patients (87.1 %) received thorough 
therapeutic recommendations during the first visit. Topical 
medication as a monotherapy was the leading method of ma-
nagement in 66.3 % of these patients. In contrast, systemic 
Figure 5 Distribution of the special 
forms of rosacea. The discrepancy 
between the total number of patients 
(158) diagnosed with special forms 
and the total number displayed on the 
Figure (166) is due to the sporadic oc-
currence of two distinct special forms 
in the same individual.
Table 2 Frequency distribution of the total patient count, 
POD and rosacea by type of treatment received during the 
first visit.







Topical treatment 596 (66.3) 133 (91.7) 463 (61.4)
Systemic treatment 51 (5.7) 1 (0.7) 50 (6.6)
Topical + systemic 
treatment
252 (28.0) 11 (7.6) 241 (32.0)
Total 899 (100) 145 (100) 754 (100)
agents alone were prescribed in less than 6 % of the cases, 
making it the least recommended form of therapy after the 
combination of topical and systemic treatments (28.0 %) 
(Table 2). Regarding specific medications, 0.75 % metroni-
dazole (gel, cream) and 40 mg modified release doxycycline 
preparation were by far the most frequently prescribed sub-
stances used in topical and systemic therapy, respectively 
(Table S1; online Supporting Information).
Discussion
Prevalence, gender and age
The prevalence of 1.4 % for patients with rosacea (nrosacea/ntotal 
= 841/60965) in the outpatient clinic of the LMU is similar 
to that found in other studies in outpatient clinics, such as 
that of Doe et al. (1.8 %) and Gutierrez et al. (2.0 %) [13, 
14]. However, there is a large variation in the general popu-
lation, ranging from below 1.0 % [15] to above 20.0 % [16]. 
Latest surveys reported a prevalence of 12.3 % in Germany 
and 5.0 % in Russia in a prospective study [17]. This seems 
to be more accurate for the general population, since previ-
ously mentioned studies with very high or low results often 
had limitations such as special cohorts or different diagnostic 
criteria [15, 16]. The prevalence of patients with rosacea seen 
in dermatology practices may be considerably higher than the 
prevalence of these patients in outpatient dermatology cli-
nics of university hospitals, because severe or complex cases 
are usually referred to university hospitals. Hence, our data 
sample from patients of the LMU outpatient clinic might re-
present a special cohort.
Patients’ gender was predominantly female (69.3 %, n = 
715/1032). Rueda et al. (76.0 %) and Khaled et al. (71.0 %) 
report similar results in clinical settings [18, 19]. Contrast 
studies of the general population report a more equal gen-
der distribution [20–22], while in some other studies an even 
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greater male percentage has been reported among patients 
[21–23]. Therefore, gender might presumably be equally dis-
tributed in the general population.
Rosacea can be considered as a disease of adulthood with 
nearly 80.0 % of patients receiving their diagnosis after the 
age of 30, based on a large observational study from the UK 
[24]. Other studies conducted in large outpatient clinics in 
countries outside Europe reported similar results (mean age 
49.0 years) [18, 19]. This is also consistent with the results 
of our study group (mean age 49.3 years). When stratified by 
gender, we found that women’s age (48.5 years) was less than 
men’s (50.9 years) at the time of the diagnosis. This is in line 
with a report of Schaefer et al., which found that women with 
rosacea were on average two years younger than men among 
the general population in Germany [21]. One reason for this 
could be an earlier diagnosis of women due either to an ear-
lier onset or to earlier consultations with the doctor.
Interestingly, at the time of the diagnosis patients with 
POD were on average 10 years younger (38.7 years) than pa-
tients with rosacea, which is in accordance with the reports 
by Malik et al. (35.7 years, 1–74 years) and Hogan et al. (31.6 
years, 1–74 years) [25, 26]. In contrast, phymatous rosacea 
was diagnosed at an average of 60.3 years, which is consis-
tent with reviews from other studies [27]. Therefore, POD 
might occur more often in younger patients, while phymat-
ous rosacea could occur in older ones.
In our study, patients with ocular rosacea received their 
diagnosis at the age of 54.0 years, which is consistent with 
the results of Akpek et al. and Lazaridou et al. [28, 29]. Ho-
wever, other special forms appeared earlier than the overall 
mean age of 49.3 years, including pediatric rosacea (mean 
age 6.4 years) and rosacea fulminans (mean age 48.4 years). 
Thorough studies about special forms are rare, but reviews of 
patients with rosacea fulminans report a rather young avera-
ge age of onset of 31.3 years [30].
Symptoms
Regarding combinations of symptoms, that of erythema and 
papules occurred most frequently (11.3 %, n = 106/942), fol-
lowed by erythema and telangiectasia (10.9 %). Our results 
tend to support the proposal of a symptom-oriented therapy 
because these primary efflorescences often occurred in vari-
ous combinations [9].
Accumulated analysis showed papules (67.9 %) as the 
most frequent symptom, closely followed by erythema 
(64.2 %). Other studies from dermatological clinics sho-
wed erythema as the most frequent symptom, followed by 
papules and pustules [19, 31], while in the general popula-
tion papules and pustules were less frequently seen [16, 17]. 
Overall, erythema is probably the most frequent symptom of 
rosacea, whereas in clinical settings it may result in a higher 
percentage of papules since it could be the higher grades of 
rosacea that prompt patients to visit the doctor.
Rhinophyma was diagnosed in 64 patients (9.3 %). Rue-
da et al. (4.8 %) and Khaled et al. (3.7 %) reported roughly 
half the prevalence that we determined in our outpatient cli-
nic [18, 19]. One reason for this could be the lighter skin type 
of the population in Germany compared to the darker skin 
types of the populations in Colombia and Tunisia, which are 
reported to be less affected by rosacea [1, 2]. In conclusion, 
phymatous changes are rare but have a higher prevalence in 
a clinical setting.
Phenotypes
Depending on the interpretation of the classification, multip-
le versions of analysis and different results would be possible. 
Our cumulated analysis showed ETR (72.7 %) as the most 
frequent form, closely followed by PPR (72.4 %). Regarding 
the most severe symptom of the phenotypes, PPR was dia-
gnosed more often (68.4 %) than ETR (22.5 %). PPR was 
the most frequent form in studies from other dermatological 
clinics [18, 19]. Only Kyriakis et al. reported a higher pre-
valence for ETR (72.0 %) than for PPR (27.9 %) in a hospi-
tal-based outpatient setting [20].
The most frequent phenotype in females was PPR 
(73.5 %, n = 490/667). However, this was influenced by 
the fact that PPR was the dominating lesion in POD too. In 
contrast, phymatous rosacea occurred more often in men 
(71.8 %, n = 56/78); this has also been reported in other stu-
dies [19, 20, 27].
PPR was clearly the dominating phenotype in our outpa-
tient hospital setting. Rosacea diathesis (transient erythema) 
and ETR are more often reported in the general population, 
whereas phymatous rosacea is rare, but more likely to be seen 
in the outpatient hospital setting than in the general popula-
tion. A better international classification is required to avoid 
confusion in the interpretation of the phenotypes of rosacea, 
given the fact that rosacea patients often present with a wide 
range of symptoms that can occur in different combinations 
and variations. This has been previously recommended and 
discussed in several studies [7, 9].
Special forms
Special forms of rosacea were diagnosed in 15.8 % (n = 
158/1000) of the analyzed patients. Data concerning the pre-
valence of special forms are scarce and there is no knowledge 
about their exact distribution.
Ocular rosacea was documented as the final diagnosis 
in 6.9 % of the analyzed patients. Here, we considered only 
patients with mild symptoms of ocular involvement such as 
blepharitis and dry eye, based on the S1 Guideline provided 
Original Article Single-center retrospective study on rosacea and POD
568 © 2020 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft. | JDDG | 1610-0379/2020/1806
by the German Society of Dermatology [12]. However, ocu-
lar involvement is estimated to occur in 20 % of patients with 
cutaneous rosacea [9]. Differences in physical examination, 
questionnaires, and in definitions of ophthalmic rosacea can 
often make differentiation difficult. Thus, it is important to 
screen patients thoroughly for ocular symptoms, and also 
consider some of the most relevant differential diagnoses, 
such as bacterial, viral, or allergic conjunctivitis, phlyctenu-
lar conjunctivitis or trauma, since they can be frequently 
overlooked [9].
We did not see steroid rosacea as often as reported by 
Khaled et al. (11.5 %) [19], which was slightly more than twice 
our result for this special form. Steroid-induced rosacea-like 
dermatitis (RD) has also been reported by other studies, such 
as Rathi et al., who described the clinical presentations of 110 
cases collected over a two-year period [32], and Teraki et al., 
who attributed 22 of the 44 RD (50 %) cases diagnosed bet-
ween 2005 and 2010 solely to topical steroid application [33]. 
Steroid rosacea is probably the second most frequent special 
form. It is therefore advisable to search for signs of steroid use.
Rosacea fulminans was diagnosed in eight cases. A great 
majority of these cases were women (6 cases, 75 %), which 
is in accordance with a recent literature review of cases from 
1916 to 2016 (123 cases, 91 %). Furthermore, pregnancy has 
been increasingly associated with this form of rosacea [30]. 
Interestingly, in our study we found that 50 % of the women 
diagnosed with rosacea fulminans were either pregnant or 
breastfeeding.
The rarest forms seen in the outpatient clinic of the 
LMU were Morbihan disease, rosacea conglobata and gram- 
negative rosacea. Several case studies of these forms have 
been reported in the literature, but they often have a very 
low number of patients. An example is a case study from 
the University of Mainz, which reported only five cases of 
Morbihan disease admitted between 2008 and 2010 [34]. 
Thus, these forms are probably less frequent.
Therapy
The lack of a single therapeutic modality leading to a cure 
of rosacea has shifted the main focus of treatment to general 
measures and symptom control of the disease [35]. In our stu-
dy, we found that a great majority of patients (94.3 %) were 
prescribed topical medication as monotherapy or in combi-
nation with systemic agents. This could be explained by the 
fact that topical treatment, alone or as part of a combinati-
on regime, has proven to be adequate in most patients with 
ETR or PPR [36], which, according to our results, were also 
the most frequent phenotypes. Moreover, due to the high re-
currence rate as a chronic inflammatory skin disease, topical 
maintenance therapy is further recommended for long-term 
improvement [35].
Limitations
This study has some limitations, including its single-center 
format. While the Dermatology Department of the LMU is 
among the largest in Europe, our chosen cohort still cannot 
accurately represent the overall epidemiology of rosacea or 
POD. Retrospective analysis of data is another limitation 
since it is disadvantageous for assessment of rare diseases, 
as can be seen in our case with the special forms of rosa-
cea, such as the gram-negative form, rosacea conglobata, or 
rosacea fulminans. Furthermore, the majority of cases were 
documented as free texts, which allows for a certain margin 
of error during retrospective assessment. Lastly, it should also 
be mentioned that this study was conducted nearly six years 
ago, which, depending on new medical and social develop-
ments, could be a potential weakness in our conclusions.
The period of three years and the large number of rosa-
cea patients studied, provided the opportunity to estimate 
an approximate frequency of rosacea forms and POD in a 
hospital-based outpatient care setting in Germany. Special 
forms are rare and make it harder for the clinician to make 
a specific diagnosis. However, it is important to be aware of 
these forms in unusual cases or cases of escalating rosacea, 
because treatment success may depend on it.
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